Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SCYNEXIS, Inc.

Market Cap 40.62M 35.01M 32.22M 30.22M 56.77M 3.84B 57.34M 381M 149M 1.88B 152M 149M 6.5B P/E Ratio 2026 *
-1x
P/E Ratio 2027 * -1.62x
Enterprise Value 40.62M 35.01M 32.22M 30.22M 56.77M 3.84B 57.34M 381M 149M 1.88B 152M 149M 6.5B EV / Sales 2026 *
35.2x
EV / Sales 2027 * 6.08x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 week-6.65%
Current month-27.84%
1 month-25.75%
3 months-43.41%
6 months-19.40%
Current year-19.55%
1 week 4
Extreme 4
4.5
1 month 4
Extreme 4
6.16
Current year 4
Extreme 4
9.12
1 year 4
Extreme 4
10.48
3 years 4
Extreme 4
30.96
5 years 4
Extreme 4
65.71
10 years 4
Extreme 4
440.8
Manager TitleAgeSince
Chief Executive Officer 61 31/12/2022
Director of Finance/CFO 65 23/10/2022
Chief Tech/Sci/R&D Officer - 30/09/2020
Director TitleAgeSince
Director/Board Member 73 30/11/2008
Chairman 67 03/06/2015
Director/Board Member 73 24/02/2015
Date Insider Type Main position Quantity % Market Cap.
03-31Buy

Chief Executive Officer

217,390 0.2736%
01-28Free

General Counsel

129,833 0.3094%
01-28Free

Chief Financial Officer

129,833 0.3094%
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-6.65%-35.19%-81.09% 40.62M
-0.09%-1.57%+39.52%+151.67% 1,007B
-0.54%-1.35%+50.62%+42.36% 567B
+0.29%-1.68%+16.12%+59.86% 392B
-0.80%+1.05%+20.91%+18.37% 328B
-0.67%+0.86%+23.90%+31.56% 277B
+0.52%-2.63%+22.70%+12.61% 275B
-1.86%+4.01%-43.73%-49.21% 196B
-0.13%+1.32%+18.11%+52.01% 189B
+2.96%+1.56%+15.00%+61.63% 154B
Average -0.03%-0.51%+12.80%+29.98% 338.61B
Weighted average by Cap. -0.15%-0.03%+27.09%+67.38%

Financials

2026 *2027 *
Net sales 1.15M 995K 915K 859K 1.61M 109M 1.63M 10.82M 4.23M 53.41M 4.33M 4.24M 185M 6.68M 5.76M 5.3M 4.97M 9.33M 631M 9.43M 62.62M 24.46M 309M 25.06M 24.53M 1.07B
Net income -41.07M -35.4M -32.58M -30.56M -57.41M -3.88B -57.99M -385M -150M -1.9B -154M -151M -6.58B -28.73M -24.76M -22.79M -21.38M -40.16M -2.72B -40.56M -269M -105M -1.33B -108M -106M -4.6B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
16/06/26 4.070 $ -0.49% 28,994
15/06/26 4.090 $ -3.31% 48,115
12/06/26 4.230 $ -0.35% 51,584
11/06/26 4.245 $ +2.29% 46,842
10/06/26 4.150 $ -4.82% 37,359
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.090USD
Average target price
33.55USD
Spread / Average Target
+720.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!